Evidence map›Paper›PMID 40025258›Full record

ArticleMolecular and cellular biochemistry2025

TCF7 functions as a prognostic biomarker in bladder cancer by strengthening EMT and stemness associated with TGF-β/SMAD3 signaling.

Congcong Zhang, Haiping Cai, Mengnan Ye, Le Wang, Weiwei Liu, Qun Huang, Xingsi Peng, Guanquan Mao, Qingling Zhang, Yan Mei

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Congcong Zhang *School of Medicine, South China University of Technology, Guangzhou, 510006, Guangdong, China.
Haiping Cai *Department of Neurosurgery, Guangdong Provincial People'S Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, Guangdong, China.
Mengnan Ye *School of Medicine, South China University of Technology, Guangzhou, 510006, Guangdong, China.
Le WangDepartment of Laboratory Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510080, Guangdong, China.
Weiwei LiuDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, Guangdong, China.
Qun HuangDepartment of Urology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.
Xingsi PengDepartment of Radiation Oncology, The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, Guangzhou, 510163, Guangdong, China.
Guanquan MaoDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, Guangdong, China. maoguanquan123@163.com.
Qingling ZhangSchool of Medicine, South China University of Technology, Guangzhou, 510006, Guangdong, China. zhangqingling@gdph.org.cn.
Yan MeiDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, Guangdong, China. meiyan@gdph.org.cn.

Funding

Basic and Applied Basic Research Foundation of Guangzhou, China 2023A04J0523GuangZhou Municipal Science and Technology Project No. 202201010343 to X.S. PengNational Natural Science Foundation of China 82203538Natural Science Foundation of Guangdong Province 2024A1515012865
6 · The paper itself

Abstract

Bladder cancer (BC) is one of the top ten most common tumors, with recurrence and metastasis being major causes of mortality among patients. A high recurrence rate is a hallmark of BC. Epithelial-mesenchymal transition (EMT) plays a role in the formation of cancer stem cells, tumor metastasis, and immune evasion. In our preliminary research, single-cell sequencing identified TCF7 as a gene associated with EMT. However, its biological function and transcriptional regulation mechanisms in BC remain unclear. This study aims to investigate TCF7's role and regulatory mechanisms in BC progression. TCF7 is a critical transcription factor promoting BC progression. High TCF7 expression in BC is significantly linked to poor patient prognosis. We uncovered a novel mechanism by which TCF7 drives EMT and stemness in BC through transcriptional regulation of TGFBR1, impacting the TGF-β/SMAD3 pathway. These findings enhance our understanding of BC progression and offer potential strategies for diagnosis, treatment, and prognosis.

Indexed as

Biomarkers, TumorEpithelial-Mesenchymal TransitionNeoplasm ProteinsNeoplastic Stem CellsReceptor, Transforming Growth Factor-beta Type ISignal TransductionSmad3 ProteinT Cell Transcription Factor 1Transforming Growth Factor betaUrinary Bladder NeoplasmsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisBiomarkers, TumorNeoplasm ProteinsReceptor, Transforming Growth Factor-beta Type ISmad3 ProteinSMAD3 protein, humanT Cell Transcription Factor 1TCF7 protein, humanTGFBR1 protein, humanTransforming Growth Factor betaBladder cancer recurrenceStemnessTCF7TGF-β/SMAD3 signaling

Identifiers

PMID40025258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.